


**Supplementary Table. Percentage of patients with a measurable change in headache severity among patients with <30% reduction in headache-day frequency.**

<i>Patients with severity response (≥1-grade improvement from baseline in severity based on patient diary)</i>			
	<b>OnabotulinumtoxinA / OnabotulinumtoxinA n=194</b>	<b>Placebo / OnabotulinumtoxinA n=261</b>	<b><i>P</i>-value</b>
<b>Week 24</b>	24.2%	13.8%	0.004
<b>Week 56</b>	54.1%	57.9%	0.428

**Supplementary Figure 1. Change from baseline in the number of severe headache days per 28-day period, among patients with <30% reduction in headache-day frequency.**

\* $P < 0.001$ , † $P < 0.05$ .



**Supplementary Figure 2. Percentage of severe headache days, pooled across patients with <30% reduction in headache-day frequency.**

\* $P < 0.001$ , † $P < 0.05$ .

